Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 2 |
Neoplasms | 2 |
Immune System Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Antibody drug conjugate (ADC) | 2 |
Monoclonal antibody | 1 |
Top 5 Target | Count |
---|---|
CDH6 x TOP1 | 1 |
TOP1 x Trop-2 | 1 |
TLR7(Toll like receptor 7) | 1 |
Target |
Mechanism TOP1 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDH6 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR7 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Sep 2024 |
Sponsor / Collaborator |
Start Date21 May 2024 |
Sponsor / Collaborator |
Start Date13 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Raludotatug deruxtecan ( CDH6 x TOP1 ) | Platinum-Resistant Ovarian Carcinoma More | Phase 3 Clinical |
Datopotamab Deruxtecan ( TOP1 x Trop-2 ) | Hormone receptor positive HER2 negative breast cancer More | Phase 3 |
DS-7011 ( TLR7 ) | Lupus Erythematosus, Cutaneous More | Phase 2 Clinical |
AW-814141 ( p38α ) | Inflammation More | Pending |
DS86760016 ( LeuRS ) | Pseudomonas Infections More | Pending |